Aster DM Quality Care's net profit more than doubled to 262 crore rupees in the second quarter

The consolidated net profit of the integrated healthcare provider Aster DM Quality Care increased by more than twofold compared to the previous year, reaching 262 crore rupees in the second quarter of the current fiscal year (Q2FY27). Revenue from operations also doubled, amounting to 2,829 crore rupees.

The company noted that Q2FY27 was the first full quarter of operation for Aster DM Quality Care following the successful merger of Aster DM Healthcare and Quality Care India. The profit growth is attributed to an increase in patient numbers, improved occupancy rate, growth in medical tourism (MVT), increased clinical complexity, and a favorable payer mix.

The results were announced during the trading session. The company's shares fell by 0.9 percent, closing at 712.9 rupees on the BSE.

Management Statements

Azad Mubin, Executive Chairman, stated that the company continues to focus on expanding its healthcare network. He mentioned the advancement of the Aster Trivandrum project towards commissioning, as well as continued investment in clinical staff, advanced infrastructure, and technology. The priority remains ensuring the best patient outcomes, strengthening operational excellence, and creating sustainable long-term value for all stakeholders.

Varun Hanna, Managing Director and Group CEO, reported that 2.2 million patients were served during the reporting period, representing a 12 percent year-on-year growth. The occupancy rate improved by 335 basis points, reaching 68 percent, reflecting increased resource utilization. A reassuring increase in complex clinical procedures was noted: robotic surgeries, kidney transplants, and joint replacements grew by approximately 39, 31, and 29 percent, respectively.

Furthermore, the company reported that medical tourism (MVT) increased by 31 percent year-on-year, despite challenging external conditions. During the quarter, the company achieved significant milestones in developing clinical capabilities, conducting a range of complex and specialized procedures across its network. The exchange of clinical experience and best practices on the unified platform allowed Care Banjara in Hyderabad to perform the first deep brain stimulation for Parkinson's disease. In Aster Medcity Kochi, the first liquid nitrogen cryoablation for breast fibroadenomas in Kerala was performed, offering a minimally invasive method for breast tissue preservation.

The company also strengthened its specialized care offerings by launching three Centers of Excellence: the Arise Robotic Spine Institute at Aster CMI, Bengaluru; the Care Cancer Institute at Ramkrishna Care, Raipur; and the Fetal Advanced Medicine Center at Aster Medcity, Kochi.

The 19 percent year-on-year revenue growth to 2,829 crore rupees was driven by higher volumes, greater clinical complexity, and a favorable payer mix, while normalized net profit (PAT) grew by 34 percent to 281 crore rupees, meeting the 10 percent PAT norm. Moving forward, the company will focus on expanding its high-tech verticals, such as CONGO (Cardiology, Oncology, Neurology, Gastroenterology, and Orthopedics), increasing capacity in various regions, strengthening clinical staff, and improving access to quality healthcare, unlocking the potential of its merged network.

Similar stories

business-standard.comNovember 4, 21:06

Apollo Hospitals' net profit grew by 32% to 630 crore rupees, revenue increased by 23%

Apollo Hospitals Enterprises (AHEL), a leading hospital chain, reported a 32% growth in consolidated net profit during the second quarter of the fiscal year 2026-27 (Q2FY27). Profit reached 630 crore rupees, compared to 477 crore rupees in the same period last fiscal year. The company's consolidated revenue increased by 23%, amounting to 7,615 crore rupees versus 6,189 crore rupees in Q2FY26.

Consolidated Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) grew by 29% to 1,191 crore rupees, while this figure was 924 crore rupees in Q2 of the last fiscal year. Krishnanan Ahileswaran, CFO of AHEL, noted that all three segments showed good results. He highlighted growth in hospitals, especially in specializations such as cardiology, oncology, gastroenterology, and orthopedics.

Furthermore, international patients increased by 37% due to the recovery of flow from Bangladesh, as well as a good influx of patients from Africa and Europe. Apollo's medical services revenue in Q2FY27 was 3,900 crore rupees, which is 23% more than the previous year. EBITDA in this segment reached 937 crore rupees, which is 20% higher than in Q2FY26, and net profit was 486 crore rupees compared to 408 crore rupees in Q2FY26, demonstrating a 19% growth.

Pratap S. Reddy, founder and chairman of the board of directors of Apollo Hospitals Group, stated that the quarterly results were supported by revenue driven by a significant increase in volume in specialized centers. He expressed satisfaction with the business progress and the contribution of each hospital to the Group.

The dividend per share from continuing operations in Q2FY27 was 43.71 rupees. Overall occupancy in Q2FY27 reached 73%, and occupancy in established units was 76%. Medical EBITDA reached 937 crore rupees, which is 20% higher. The company plans to expand its infrastructure, having 5,800 beds in total capacity and 4,700 beds over the next five years, with capital expenditure financing of 7,100 crore rupees to be done through internal accruals.

The AHLL segment, dealing with diagnostics and retail, demonstrated a 20% year-on-year revenue growth in Q2FY27. Diagnostic business revenue grew by 24% year-on-year. Within the HealthCo segment, another 222 stores were added, bringing the total number to 222. Gross Merchandise Value (GMV) grew by 27% to 571 crore rupees in Q2FY27, exceeding 450 crore rupees in Q2FY26.

Reddy also reported on the construction progress of hospitals in Hyderabad Financial District, Sonarpur in Kolkata, and Sarjapur in Bengaluru, which were commissioned in Q1 FY27. Additionally, the facility in Gurugram remains on schedule for commissioning in Q3 FY27.

business-standard.comNovember 4, 17:13

Dr Lal PathLabs' profit grew by 27.5% in the second quarter to 194 crore rupees due to volume growth

Dr Lal PathLabs, a major diagnostic operator based in Delhi, reported a 27.5% year-on-year growth in consolidated net profit for the September quarter (Q2) of the fiscal year 2026-27 (FY27). This growth was achieved through an increase in testing revenues.

The company's net profit in Q2 FY27 amounted to 194 crore rupees, which is higher than the 152 crore rupees recorded during the same period last year. The main driver of this growth was the increase in sample volumes, which rose by 13.6% year-on-year to reach 28.8 million.

Furthermore, patient coverage in the network increased by 9% year-on-year, reaching 9 million in September, compared to 8.2 million in the same period the previous year. Consequently, the network's revenue increased by 19.6% year-on-year, reaching 874 crore rupees compared to 731 crore rupees in Q2 FY26.

Shankha Banerjee, CEO of DLPL, noted that there is a growing demand for high-complexity testing and specialized analyses, supported by increased awareness among doctors and patients. Operationally, the EBITDA margin increased by 25%, reaching 280 crore rupees from 224 crore rupees, and the EBITDA margin improved to 32.1% from 30.7%.

He also added that the company's future focus will be on expanding access to advanced diagnostics by strengthening capabilities in areas such as genomics, oncology, reproductive health, transplant diagnostics, and rare diseases.

As of September 30, 2026, DLPL, the largest provider of diagnostic services in India, operates 312 clinical laboratories, including the national reference laboratory in Delhi and regional reference laboratories in Kolkata, Bengaluru, and Mumbai. The network also includes 7,727 Patient Service Centers (PSC) and 13,935 Pickup Points (PUP), serving private patients, hospitals, healthcare professionals, and corporate clients.

DLPL's board of directors also approved an additional investment of up to 49.5 crore rupees in its wholly-owned subsidiary in Dubai, Dr Lal PathLabs FZCO, to meet its business and operational needs. In regulatory filings, DLPL indicated that this subsidiary will make further investments in its subsidiary Sunshine Healthcare Limited (SHL) in Ghana.

The results were announced during market trading. DLPL shares closed on the BSE on Wednesday 5.1% higher, at a price of 2,028.95 rupees per share.

business-standard.comOctober 30, 15:18

Max Healthcare's second-quarter profit grew by 10% to 448 crore rupees due to increased bed occupancy

Max Healthcare Institute Ltd reported a 10.34% increase in net profit after tax for the network to 448 crore rupees for the September quarter of fiscal year 27. Meanwhile, the network's gross revenue increased by 20%, reaching 3,219 crore rupees, driven by higher bed occupancy and demand from international patients.

Previously, during the same period last year, the company reported a net profit after tax of 406 crore rupees. The network's gross revenue was 3,219 crore rupees, reflecting a 20% growth, mainly due to an increase in occupied bed days (OBDs).

Revenue from international patients reached 307 crore rupees, showing a 33% increase and accounting for about 10% of the hospital's total revenue. Free cash flow from operating activities amounted to 500 crore rupees compared to 291 crore rupees in the second quarter of fiscal year 26. Of this amount, 292 crore rupees was allocated to current expansion plans, and 195 crore rupees to dividends.

During the quarter, the company's board of directors approved capital expenditures of 415 crore rupees to add 209 beds as part of modernization projects for existing hospitals to increase capacity. These plans include 85 beds in MSSH, Noida, and 60 beds in MSSH, Vaishali. Additionally, BLK Max will add 64 beds along with a multi-level parking tower to support the increased flow of patients and visitors.

For the half-year ending in September, the total bed capacity reached 6,184, representing a 20% increase compared to the previous year. The network's gross revenue was 6,200 crore rupees, which is 18% more than in the corresponding period last fiscal year, also caused by an increase in OBDs. The network's net profit reached 805 crore rupees compared to 750 crore rupees in the corresponding period last fiscal year.

Abhay Soi, Chairman and Managing Director of Max Healthcare Institute Ltd, noted that the occupancy rate of newly added beds is growing faster, indicating high demand and absorption of additional capacity. He also emphasized that medical tourism is showing strong growth, supported by the price competitiveness of medical services in India, strengthening the country's position as a leading global healthcare destination.